Committed to providing comprehensive support for global drug development

 The IL-1 family comprises 11 cytokines, including 7 ligands with agonist activity (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ), and 4 members with antagonistic activity [IL-1 receptor antagonist (IL-1Rα), IL-36Ra, IL-37, IL-38]. IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, and IL-36γ activate MPKK and NF-κB, leading to inflammatory responses.

Upon release, mature IL-18 initiates signal transduction primarily by binding to receptor complexes on the surface of target cells. It first binds to the IL-18 receptor α-chain (IL-18Rα), subsequently recruiting the IL-18 receptor β-chain (IL-18Rβ) to form a heterotrimer; this process primarily occurs on immune cells such as T cells and NK cells. This complex recruits the adaptor protein MyD88, ultimately activates key signaling pathways such as NF-κB and MAPK, inducing the expression of inflammation-related genes. To prevent excessive inflammatory responses, the human body possesses an efficient “braking” system—IL-18-binding protein (IL-18BP)—which captures free IL-18 with extremely high affinity, blocking its binding to receptors and thereby precisely regulating the biological activity of IL-18.

 IL-18 Effector Reporter Cells (Suspension) stably express human IL-18Rα and human IL-18Rβ in recombinant cells that are regulated by regulatory factors and express a reporter gene.

Reporter cell models effectively reflect molecular mechanisms of action while offering lower variability and improved operability. They have been widely adopted by the China National Institute for the Control of Pharmaceutical and Biological Products (CNIC) and pharmaceutical companies for the assay of antibody drug bioactivity, playing a significant role in drug R&D, quality control, and batch release.

The IL-18 Effector Reporter Cell (Suspension) model effectively mimics the in vivo IL-18 signaling pathway; the underlying mechanism is illustrated in the figure below.

Figure 1. Schematic diagram of the IL18 Effector Reporter cell model

Figure 2.Dose Response of Recombinant Human IL18 in IL18 Effector Reporter Cell(Suspension,C12).

Figure 3.Inhibition of hIL18-Induced Reporter Activity by Recombinant Human IL18BP Protein in IL18 Effector Reporter Cell(Suspension,C12).

Cell Passage Procedures

1.This cell line grows in suspension.
2.Upon receipt, cells should be thawed immediately or stored in liquid nitrogen until use.
3.Before thawing, pre-warm the water bath and culture medium to 37 °C, and prepare a small amount of dry ice.
4.Remove the cryovial from storage and transport it to the cell culture laboratory on dry ice.
5.Rapidly thaw the cells in a 37 °C water bath. Once the cells are completely thawed, spray the cryovial with 70% ethanol for disinfection and transfer it to a biosafety cabinet.
6.Add 10 mL of pre-warmed culture medium into a 15 mL centrifuge tube. Transfer the contents of the cryovial into the tube and centrifuge at 1000 rpm for 5 minutes.
7.Carefully discard the supernatant. Resuspend the cell pellet in 5 mL of pre-warmed culture medium by gentle pipetting. Immediately perform cell counting and adjust the cell density to 3–6 × 10⁵ cells/mL based on the counting results, then transfer the cells into a culture flask.
8.Count the cells every 1–2 days. When the cell density exceeds 1 × 10⁶ cells/mL, passage the cells promptly or add fresh culture medium. Maintain the cell density between 2 × 10⁵ and 1 × 10⁶ cells/mL.

Suspension Cell Cryopreservation Procedure:

1.Collect 8 × 10⁶ cells, centrifuge, and discard the supernatant.
2.Add 1 mL of cell freezing medium (90% FBS + 10% DMSO) and gently pipette to mix thoroughly. Transfer the suspension into a cryovial.
3.Immediately place the cryovial into a controlled-rate freezing container (Nalgene 5100-0001), fill with isopropanol up to the indicated level, and store at −80 °C.
4.After 24 hours, transfer the cryovial to liquid nitrogen for long-term storage.